Citations

Clear

246 citation(s) found for "Study, Alfa".

O2‐03‐02: are White Matter Hyperintensities a Core Feature of Alzheimer’s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN)
Zimmerman, Molly E. , Viqar, Fawad, Narkhede, Atul, Benzinger, Tammie Lee Smith, Marcus, Daniel S., Cairns, Nigel J. , Buckles, Virginia, Saykin, Andy J., Ringman, John M. , Ryan, Natalie S. , Förster, Stefan , Laske, Christoph , Salloway, Stephen , Correia, Stephen , Weiner, Michael W. , Mayeux, Richard , Lee, Seonjoo , Tosto, Giuseppe , Goate, Alison , Fox, Nick C. , Holtzman, David M. , Ghetti, Bernardino , McDade, Eric , Martins, Ralph N. , Saykin, Andy J., Masters, Colin L. , Schofield, Peter R. , Sperling, Reisa Anne , Bateman, Randall J. , Morris, John C. , Jack, Clifford R. , Brickman, Adam M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2016.06.406 Get It

Magnetic resonance imaging–guided laser interstitial thermal therapy for previously treated hypothalamic hamartomas
Burrows, Anthony M. , Marsh, W. Richard , Woodrum, David A. , Pollock, Bruce E. , Gorny, Krzysztof R. , Felmlee, Joel P. , Watson, Robert E. , Goerss, Steven, Worrell, Gregory A. , Kaufmann, Timothy J. , Goerss, S, Gompel, Jamie J. Van

Mayo Clinic

Neurosurgical Focus | October 1, 2016 | Volume: 41 | Issue: 4 | Pages: E8

10.3171/2016.7.focus16218 | PMID 27690651 Get It

OBJECTIVE Hypothalamic hamartomas (HHs) are associated with gelastic seizures and the development of medically refractory epilepsy. Magnetic resonance imaging–guided laser interstitial thermal therapy (MRg-LITT) is a minimally invasive ablative treatment that may have applicability for these deep-seated lesions. Here, the authors describe 3 patients with refractory HHs who they treated with MRg-LITT. METHODS An institutional review board–approved prospective database of patients undergoing Visualase MRg-LITT was retrospectively reviewed. Demographic and historical medical data, including seizure and medication histories, previous surgeries, procedural details, and surgical complications, along with radiological interpretation of the HHs, were recorded. The primary outcome was seizure freedom, and secondary outcomes included medication reduction, seizure frequency, operative morbidity, and clinical outcome at the latest follow-up. RESULTS All 3 patients in the multi-institutional database had developed gelastic seizures related to HH at the ages of 7, 7, and 9 years. They presented for further treatment at 25, 28, and 48 years of age, after previous treatments with stereotactic radiosurgery in all cases and partial hamartoma resection in one case. One ablation was complicated by a small tract hemorrhage, which was stable on postoperative imaging. One patient developed hyponatremia and experienced weight gain, which were respectively managed with fluid restriction and counseling. At the most recent follow-up at a mean of 21 months (range 1–32 months), one patient was seizure free while another had meaningful seizure reduction. Medication was reduced in one case. CONCLUSIONS Adults with gelastic seizures despite previous treatments can undergo MRg-LITT with reasonable safety and efficacy. This novel therapy may provide a minimally invasive alternative for primary and recurrent HH as the technique is refined.
Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents
Kopruszinski, Caroline Machado , Xie, Jennifer Y. , Eyde, Nathan, Walter, Sarah , Stratton, Jennifer , Bigal, Marcelo E. , Chichorro, Juliana Geremias , Dodick, David, Remeniuk, Bethany , Dodick, David W. , Porreca, Frank , Kopruszinski, Caroline

Mayo Clinic

Cephalalgia | May 22, 2016 | Volume: 37 | Issue: 6 | Pages: 560-570

10.1177/0333102416650702 | PMID 27206958 Get It

Objective The objective of this study was the determination of the role of calcitonin gene-related peptide (CGRP) in the induction of medication overuse headache (MOH)-related migraine in an injury-free preclinical model. Methods Rats were primed by a 7-day period of exposure to acute migraine therapies including sumatriptan and morphine. After an additional 14-day drug-free period, rats were exposed to putative migraine triggers including bright light stress (BLS) or nitric oxide (NO) donor in the presence or absence of TEV48125, a fully humanized CGRP antibody. Cutaneous allodynia (CA) was used as an outcome measure and CGRP blood and cerebrospinal fluid (CSF) levels were measured. Results BLS and NO donor challenge evoked delayed, long-lasting CA selectively in rats that were previously treated with sumatriptan or morphine. BLS produced a significant increase in CGRP in the plasma, but not CSF, in animals that were previously exposed to sumatriptan compared to saline controls. TEV48125 did not modify baseline tactile thresholds or produce behavioral side effects, but significantly inhibited both BLS- and NO donor-induced CA in animals that were previously primed with sumatriptan or morphine; an isotype control protein that does not bind CGRP had no effect. Interpretation These data suggest that acute migraine medications may promote MOH in susceptible individuals through CGRP-dependent mechanisms and that anti-CGRP antibodies may be a useful clinical strategy for the treatment of MOH.
MRI-Guided Stereotactic System for Delivery of Intraspinal Microstimulation
Grahn, Peter J. , Goerss, Stephan J., Mallory, Grant W., Kall, Bruce A., Mendez, Aldo A. , Trevathan, James K. , Felmlee, Joel P. , Bennet, Kevin E. , Lee, Kendall H. , Luján, J. Luis , Trevathan, James K

Mayo Clinic

Spine | December 16, 2015 | Volume: 41 | Issue: 13 | Pages: E806-E813

10.1097/brs.0000000000001397 | PMID 26679880 Get It

Study Design. Laboratory/animal-based proof of principle study. Objective. To validate the accuracy of a magnetic resonance imaging (MRI)-guided stereotactic system for intraspinal electrode targeting and demonstrate the feasibility of such a system for controlling implantation of intraspinal electrodes. Summary of Background Data. Intraspinal microstimulation (ISMS) is an emerging preclinical therapy, which has shown promise for the restoration of motor function following spinal cord injury. However, targeting inaccuracy associated with existing electrode implantation techniques remains a major barrier preventing clinical translation of ISMS. Methods. System accuracy was evaluated using a test phantom comprised of nine target locations. Targeting accuracy was determined by calculating the root mean square error between MRI-generated coordinates and actual frame coordinates required to reach the target positions. System performance was further validated in an anesthetized pig model by performing MRI-guided intraspinal electrode implantation and stimulation followed by computed tomography of electrode location. Finally, system compatibility with a commercially available microelectrode array was demonstrated by implanting the array and applying a selection of stimulation amplitudes that evoked hind limb responses. Results. The root mean square error between actual frame coordinates and software coordinates, both acquired using the test phantom, was 1.09 ± 0.20 mm. Postoperative computed tomography in the anesthetized pig confirmed spatially accurate electrode placement relative to preoperative MRI. Additionally, MRI-guided delivery of a microwire electrode followed by ISMS evoked repeatable electromyography responses in the biceps femoris muscle. Finally, delivery of a microelectrode array produced repeatable and graded hind limb evoked movements. Conclusion. We present a novel frame-based stereotactic system for targeting and delivery of intraspinal instrumentation. This system utilizes MRI guidance to account for variations in anatomy between subjects, thereby improving upon existing ISMS electrode implantation techniques. Level of Evidence: N/A